Oncology and Gastroenterology are two areas of study in which Hartmut Goldschmidt engages in interdisciplinary work. He performs multidisciplinary study in the fields of Gastroenterology and Internal medicine via his papers. He regularly links together related areas like Thalidomide in his Internal medicine studies. Hartmut Goldschmidt performs multidisciplinary studies into Thalidomide and Lenalidomide in his work. He combines Lenalidomide and Dexamethasone in his research. His work blends Dexamethasone and Chemotherapy studies together. While working in this field, Hartmut Goldschmidt studies both Chemotherapy and Salvage therapy. His research on Salvage therapy often connects related topics like Surgery. Surgery and Transplantation are commonly linked in his work.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade.
Lancet Oncology (2014)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin.
The New England Journal of Medicine (2005)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel.
The New England Journal of Medicine (2016)
Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
Pieter Sonneveld;Ingo G.H. Schmidt-Wolf;Bronno Van Der Holt;Laila El Jarari.
Journal of Clinical Oncology (2012)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy.
Lancet Oncology (2013)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua.
Lancet Oncology (2016)
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Pieter Sonneveld;Hervé Avet-Loiseau;Sagar Lonial;Saad Usmani.
Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma.
Rainer Haas;Robert Möhle;Stefan Frühauf;Hartmut Goldschmidt.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: